US Patent

US8598210 — Prolyl hydroxylase inhibitors and methods of use

Composition of Matter · Assigned to Akebia Therapeutics Inc · Expires 2027-06-26 · 1y remaining

Vulnerability score 30/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a prolyl hydroxylase inhibitor, specifically a compound called VADADUSTAT, and its methods of use for treating various diseases.

USPTO Abstract

The present disclosure relates to HIF-1alpha prolyl hydroxylase inhibitors, compositions which comprise the HIF-1alpha prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.

Drugs covered by this patent

Patent Metadata

Patent number
US8598210
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-06-26
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Akebia Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.